About the session

While circulating cell-free DNA (ccfDNA), and to some extent circulating tumor cells (CTCs) from blood are routinely used as analytes in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) has recently also gained relevance for biomarker studies. The combination of insights from different analytes promises increased understanding of molecular processes in tumor biology. However, there are still challenges to overcome in the preanalytical workflow, such as defining suitable blood collection tubes for optimal assay sensitivity. In this session, we show the multianalyte use of the PAXgene Blood ccfDNA Tube (RUO) for plasma extraction as part of a liquid biopsy workflow. Learning objectives: the need for blood stabilization for ccfDNA analysis and impact on assay sensitivity and multianalyte applications for liquid biopsy research.


Andrea Huxhold
Dr. Andrea Huxhold is a Senior Global Marketing Manager and joined QIAGEN in 2014 as a product development scientist at the joint venture with BD, PreAnalytiX. She developed the PAXgene Blood ccfDNA Tube and QIAsymphony PAXgene Blood ccfDNA Kit. Prior to joining QIAGEN Andrea graduated from Philipps University Marburg as Human Biologist and earned her PhD in the Institute of Biochemistry and Molecular Biology at University Clinic in Aachen, Germany.